<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002495</url>
  </required_header>
  <id_info>
    <org_study_id>VMCAD-001/B</org_study_id>
    <nct_id>NCT01002495</nct_id>
  </id_info>
  <brief_title>Gene Therapy for the Treatment of Chronic Stable Angina</brief_title>
  <official_title>A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helixmith Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helixmith Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of catheter based&#xD;
      injections of VM202 into the heart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I/II, open label, dose-escalation, multicenter, 12 month study designed to assess the&#xD;
      safety and tolerability of catheter based percutaneous myocardial injection of VM202 in&#xD;
      patients with chronic refractory myocardial ischemia. The study will consist of three (3)&#xD;
      cohorts with a total of 4 subjects enrolled in each cohort. Endocardial injections will be&#xD;
      performed with the MyoStar Injection Catheter under guidance of the NOGA XP Cardiac&#xD;
      Navigation System.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was never initiated at any sites.&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary study objective is to evaluate safety and tolerability of a catheter-based, endocardial injection of different doses of VM202.</measure>
    <time_frame>Days 1, 7, 14, 21, 30, 60, and 90, 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives include the assessment of the angiogenic potential of VM202</measure>
    <time_frame>one month, three months, six months and twelve months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measures include exercise treadmill test, SPECT, cardiac MRI and change in use of anti-anginal medications.</measure>
    <time_frame>Days 1, 7, 14, 21, 30, 60, and 90. 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight endocardial injection for a total dose of 1mg VM202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight endocardial injections for a total dose of 2mg VM202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve endocardial injections for a total dose of 3mg VM202</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM202</intervention_name>
    <description>Endocardial injections on Day 0.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 21 years, but less than or equal to 75 years.&#xD;
&#xD;
          -  Stable chronic refractory angina classified as Canadian Cardiovascular Society (CCS)&#xD;
             functional class II - IV&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) of ≥30% and ≤ 50%;&#xD;
&#xD;
          -  Clinical signs and symptoms of significant ischemia by treadmill test or Stress&#xD;
             imaging (SPECT, Echo or CARDIAC MRI acceptable)&#xD;
&#xD;
          -  Subjects must be able to complete a minimum of 3 minutes, but no more than 10 minutes&#xD;
             on a Modified Bruce treadmill protocol.&#xD;
&#xD;
          -  Patients on maximal medical therapy including at least 2 of the following (unless&#xD;
             hemodynamic parameters or intolerance contraindicate their use):(a) Long acting&#xD;
             nitrate, (b) Beta Blocker or (c) Calcium Channel Blocker (d) Ranolazine. Optimal&#xD;
             medical regimen for each subject will be decided by the referring cardiologist or&#xD;
             principal investigator. Patients must be on stable medical regimen for 30 days prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Coronary angiogram within 1 year to confirm the presence of coronary disease which is&#xD;
             not amenable to standard revascularization procedures.&#xD;
&#xD;
          -  Candidates must not be eligible for any other revascularization procedures. The&#xD;
             participant and his/her coronary film must have been discussed with an independent&#xD;
             cardiac surgeon and must have been denied for CABG or PTCA. Participants who are&#xD;
             marginal or poor candidates for conventional revascularization will be considered&#xD;
             eligible if the risks of performing a CABG or PTCA procedure outweigh the potential&#xD;
             benefit and/or such a procedure is unlikely to offer a worthwhile clinical benefit.&#xD;
             The criteria defining such cases may include, but may not be limited to, the following&#xD;
             examples:&#xD;
&#xD;
               -  Diffuse or distal vessel disease&#xD;
&#xD;
               -  Chronic occlusions&#xD;
&#xD;
               -  Unprotected left main stenosis&#xD;
&#xD;
               -  Tortuous or severely angulated vessels&#xD;
&#xD;
               -  Severely calcified vessels&#xD;
&#xD;
               -  Small vessels (&lt; 2.5mm)&#xD;
&#xD;
          -  Subjects with childbearing potential must take acceptable measure to prevent pregnancy&#xD;
             during the course of the study.&#xD;
&#xD;
          -  Subject capable of understanding with the protocol and signing the informed consent&#xD;
             document prior to any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have undergone a successful revascularization procedure within 6 months&#xD;
             of enrollment;&#xD;
&#xD;
          -  MI, unstable angina requiring &gt; 24 hour hospitalization, or percutaneous coronary&#xD;
             intervention, within last 90 days;&#xD;
&#xD;
          -  Stroke or TIA within last 180 days;&#xD;
&#xD;
          -  Predominant CHF symptoms;&#xD;
&#xD;
          -  Hemodynamically significant severe primary valvular heart disease, unless corrected by&#xD;
             a properly functional prosthetic valve;&#xD;
&#xD;
          -  Uncontrolled hypertension as defined as systolic BP 170 mmHg or diastolic &gt; 90 mmHg at&#xD;
             baseline/ screening evaluation;&#xD;
&#xD;
          -  Sustained ventricular tachycardia or automatic implantable cardiodefibrillator (AICD)&#xD;
             firing within last 180 days;&#xD;
&#xD;
          -  History of ventricular fibrillation;&#xD;
&#xD;
          -  Use of the MyoStar catheter may not be appropriate for patients with prosthetic&#xD;
             valves. Patients with a mechanical valve at risk for injury due to the interventional&#xD;
             approach should be excluded;&#xD;
&#xD;
          -  Subjects with any comorbidity that may interfere with the ability to perform a maximal&#xD;
             treadmill test (e.g. severe arthritis, musculoskeletal disorders, COPD);&#xD;
&#xD;
          -  Subjects with a history of malignancy, a known active malignancy, or a new screening&#xD;
             finding of malignant neoplasm;&#xD;
&#xD;
          -  Patients with family history of colon cancer in any first degree relative unless they&#xD;
             have undergone a colonoscopy in the last 12 months with negative findings;&#xD;
&#xD;
          -  Elevated PSA unless prostate cancer has been excluded;&#xD;
&#xD;
          -  Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that&#xD;
             preclude standard ophthalmologic examination.&#xD;
&#xD;
               -  Cataract surgery within 6 months of trial;&#xD;
&#xD;
               -  Vascular lesions of the anterior segment of the eye (infection or ulceration of&#xD;
                  the cornea, rubeotic glaucoma, etc);&#xD;
&#xD;
               -  Vascular lesions of the posterior segment of the eye or proliferative retinopathy&#xD;
                  in diabetics, macular edema, s/p photocoagulation for macular edema or&#xD;
                  proliferative retinopathy; nondiabetics with central or branch retinal vascular&#xD;
                  occlusions, sickle cell retinopathy, ischemic retinopathy due to retinal venous&#xD;
                  stasis or carotid artery disease);&#xD;
&#xD;
               -  Choroidal new vessels associated with age-related macular degeneration, myopic&#xD;
                  degeneration, presumed ocular histoplasmosis syndrome, angioid streaks,&#xD;
                  pseudoxanthoma elasticum, or without ocular disease; and&#xD;
&#xD;
               -  Large elevated choroidal nevi, choroidal vascular tumors (choroidal hemangioma),&#xD;
                  or melanomas.&#xD;
&#xD;
          -  Chronic inflammatory disease (e.g. Crohn, Rheumatoid Arthritis);&#xD;
&#xD;
          -  Active infectious disease and/or known to have tested positive for human&#xD;
             immunodeficiency virus (HIV), human t lymphotrophic virus (HTLV), hepatitis B virus&#xD;
             (HBV), or hepatitis C virus (HCV);&#xD;
&#xD;
          -  Specific laboratory values at Screening including: Hemoglobin &lt; 9.0, g/dL, WBC &lt; 3,000&#xD;
             cells per microliter, platelet count &lt;75,000/mm3, Creatinine &gt; 2.0 mg/dL, AST and/or&#xD;
             ALT &gt; 3 times the upper limit of normal or any other clinically significant lab&#xD;
             abnormality which in the opinion of the investigator should be exclusionary;&#xD;
&#xD;
          -  Patients have undergone enhanced external pulsation (EECP) treatment within the last 6&#xD;
             months;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Severe comorbidity associated with a reduction of life expectancy of less than 1 year;&#xD;
&#xD;
          -  Exposure to any previous experimental angiogenic therapy and/or myocardial laser&#xD;
             therapy; or therapy with another investigational drug within 180 days of enrollment or&#xD;
             participation in any concurrent study that may confound the results of this study;&#xD;
&#xD;
          -  Major psychiatric disorder in past 6 months;&#xD;
&#xD;
          -  History of recent tobacco abuse (within past &lt; 5 years);&#xD;
&#xD;
          -  Known drug or alcohol dependence or any other factors which will interfere with the&#xD;
             study conduct or interpretation of the results or who in the opinion of the&#xD;
             investigator are not suitable to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2009</study_first_submitted>
  <study_first_submitted_qc>October 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial</keyword>
  <keyword>ischemia</keyword>
  <keyword>coronary disease</keyword>
  <keyword>angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

